Kazumi Yoshizawa

Prof. Kazumi Yoshizawa


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2017 in Synapse
Verified
Journal Article
Closed access
PDF file
KYKazumi Yoshizawa
Kazumi Yoshizawa
AOAyano Okumura
Ayano Okumura
KNKozue Nakashima
Kozue Nakashima
TSTomoyo Sato
Tomoyo Sato
THTatsuya Higashi
Tatsuya Higashi

26 September 2020 in Synapse
Verified
Journal Article
Closed access
PDF file
KYKazumi Yoshizawa
Kazumi Yoshizawa
KTKota Takeuchi
Kota Takeuchi
TNToka Nakamura
Toka Nakamura
SUSaki Ukai
Saki Ukai
YTYukino Takahashi
Yukino Takahashi
STSei‐Ichi Tanuma
Sei‐Ichi Tanuma

1 November 2018 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
Akiyoshi SaitohAkiyoshi Saitoh
Akiyoshi Saitoh
ASAkinobu Soda
Akinobu Soda
SKShuhei Kayashima
Shuhei Kayashima
KYKazumi Yoshizawa
Kazumi Yoshizawa
JOJun-Ichiro Oka
Jun-Ichiro Oka
MYMitsuhiko Yamada
Mitsuhiko Yamada
We previously reported that systemic administration of a delta opioid receptor (DOP) agonist, KNT-127, produced a potent anxiolytic-like effect in rats. Interestingly, DOPs are highly distributed in the prelimbic medial prefrontal cortex (PL-PFC). In the present study, we investigated the effect of KNT-127 co-perfusion in the PL-PFC on anxiety-like behavior in mice, induced by a glial glutamate transporter inhibitor, (3S)-3-[[3-[[4-(Trifluoromethyl)benzoyl]amino]phenyl]methoxy]-l-aspartic acid (TFB-TBOA). Extracellular glutamate levels were measured in male C57BL/6N mice by in vivo microdialysis high-performance liquid chromatography/electrochemical detection, with behavior simultaneously assessed in the open field test. As expected, extracellular glutamate levels were significantly increased, and anxiety-like behavior was induced after local perfusion of TFB-TBOA in the PL-PFC. Uniquely, co-perfusion of KNT-127 in the PL-PFC diminished anxiety-like behavior induced by TFB-TBOA without affecting extracellular glutamate levels. Further, the effect of KNT-127 on anxiety-like behavior was antagonized by a selective DOP antagonist, naltrindole, suggesting that KNT-127 acts via DOPs. These findings do not support our preconceived hypothesis that KNT-127 in PL-PFC produces an anxiolytic-like effect via suppression of glutamatergic transmission. Hence, further studies are necessary to understand the mechanisms of DOP agonist-induced anxiolytic-like effects in the PL-PFC.

2 June 2020 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
KYKazumi Yoshizawa
Kazumi Yoshizawa
MTMizuho Tabuchi
Mizuho Tabuchi
SUSaki Ukai
Saki Ukai
HSHidetaka Suzuki
Hidetaka Suzuki
YKYohei Kawano
Yohei Kawano
RTRyoko Takasawa
Ryoko Takasawa
Background/Aim: This study aimed to determine the anxiolytic effect of a putative glyoxalase 1 inhibitor, piceatannol, as well as its antitumor activities on the stress-induced tumor growth of Lewis lung carcinoma. Materials and Methods: The anxiolytic activities of piceatannol (1-30 mg/kg) were assessed using the elevated plus maze (EPM) test. We also evaluated the pharmacological modulation of stress-induced tumor growth; the mice were treated with piceatannol (3 and 30 mg/kg) from the 10th day till the 19th day after administration of the LLC cells. Results: At the low dose (3 mg/kg), piceatannol significantly increased the time spent in the open arms of the EPM test when compared with the vehicle. At higher doses (30 mg/kg), it significantly suppressed the stress-induced enhancement of tumor growth. Conclusion: A low dose of piceatannol exerts an anxiolytic effect, and high doses have an antitumor effect.

1 January 2013 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
KYKazumi Yoshizawa
Kazumi Yoshizawa
TMTomohisa Mori
Tomohisa Mori
TUTamami Ueno
Tamami Ueno
MNMizuki Nishiwaki
Mizuki Nishiwaki
MSMasahiro Shibasaki
Masahiro Shibasaki
TSTsutomu Suzuki
Tsutomu Suzuki
We have demonstrated previously that the ketamine-induced discriminative stimulus effect is likely to reflect the phencyclidine-like psychotomimetic effects. Therefore, the present study was designed to investigate the effects of the antipsychotics and 5-HT2 receptor antagonist on the discriminative stimulus effects of ketamine in rats. While sulpiride did not attenuate the discriminative stimulus effects of ketamine, both clozapine and ketanserin attenuated those of ketamine, suggesting that the discriminative stimulus effects of ketamine are mediated by multiple receptors, especially the 5-HT2 receptor, but not the D2 receptor. Furthermore, our findings imply that atypical antipsychotics could be useful for the treatment of psychotomimetic effects induced by ketamine.

3 May 2021 in Cancer Diagnosis & Prognosis
Verified
Journal Article
Closed access
KYKazumi Yoshizawa
Kazumi Yoshizawa
RKRuka Kurono
Ruka Kurono
HSHaruka Sato
Haruka Sato
EIErika Ishijima
Erika Ishijima
HNHaruka Nasu
Haruka Nasu
KNKenichi Negishi
Kenichi Negishi
Background/Aim: Fatigue is the most common symptom in patients with cancer undergoing radiation therapy or cancer chemotherapy. However, cancer-related fatigue remains undertreated and poorly understood. Materials and Methods: Mice were administered a single dose of cisplatin (10 mg/kg, intraperitoneally) or saline (as a control) and then treated with sucrose, fructose, glucose (each at 500 or 5,000 mg/kg, orally), or saline (control) daily for 4 days. cisplatin-induced fatigue-like behavior was investigated by assessment of running activity on a treadmill. The influence of glucose intake on tumor growth was also examined in Lewis lung carcinoma (LLC)-bearing mice. Results: Administration of sucrose and glucose improved cisplatin-induced fatigue-like behavior in mice, whereas administration of fructose showed only slight antifatigue effects. Although glucose-fed mice showed increased tumor growth, this was balanced out by the powerful cytotoxicity of cisplatin. Conclusion: Sucrose, and especially glucose, may improve patient quality of life during treatment with anticancer agents by preventing fatigue without interfering with the antitumor effects of cisplatin.